By Michael M. Rosen
In a riveting tale of legislative sentence structure, history, and policy, the full Court of Appeals for the Federal Circuit held in Ariad v. Lilly, No. 2008-1248, that Ariad Pharmaceuticals' patent claims were invalid because they did not contain a sufficiently detailed description of its claimed invention - a method for reducing activity of a gene transcription factor.
While the ruling didn't come as muc...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In